Texas based plasmid CMO VGXI breaks ground on facility expansion and new flex-scale GMP production plants.
The Woodlands, TX – February 22, 2018 – VGXI announced today they have broken ground on a 5,000 square foot expansion of their Texas based manufacturing facility. Once complete, the project will increase the company’s footprint by 17% and its cGMP manufacturing space by over 70%.
VGXI was founded in 1997 and has been operating as a GMP plasmid contract manufacturing organization (CMO) since 2004. Over the 15 year period, the company has continued to grow in response to an increasing demand for high quality DNA, with its most recent expansion completed in 2016.
The upcoming development will add two new flexible-use GMP production areas to serve clients with both large and small scale needs, and a range of products from DNA vaccines to plasmid raw material for GMP viral vector production. “With three key approvals in 2017 for CAR-T and AAV therapies, the gene therapy industry is rapidly maturing,” said VGXI’s president and CEO, Young Park. “We are excited to support the needs of our growing client base with increased flexibility and capacity across all service levels from Pre-Clinical to Highly Documented (HD) and cGMP grade plasmid production.”
With over 15 years of experience, VGXI, Inc. is a leading provider of plasmid DNA manufacturing and development services for DNA vaccine and gene therapy research. The company has an outstanding track record of success in manufacturing plasmid products under cGMP conditions for clinical trials in the US, EU, Asia and Australia, and its cGMP and non-GMP products have passed rigorous reviews by several international regulatory agencies. VGXI’s ability to work with unique requirements and create custom manufacturing solutions is based on its patented manufacturing process, flexible cGMP production facility, and experienced development team. VGXI, Inc. is a wholly-owned subsidiary CMO of GeneOne Life Science, Inc.
ABOUT GENEONE LIFE SCIENCE
GeneOne Life Science Inc. is an international DNA vaccine developer and leading contract manufacturer of DNA plasmid-based agents for pre-clinical and clinical trials for global companies and institutions. It researches and develops DNA vaccines to prevent and treat incurable diseases in South Korea and internationally. The company is headquartered in Seoul, South Korea. VGXI, Inc., GeneOne’s wholly-owned manufacturing subsidiary located in Texas, is the largest pure-play cGMP DNA plasmid manufacturing facility in the world. For more information, visit http://www.genels.com/en.
Cautionary Factors That May Affect Future Results
Materials in this press release contain information that includes or is based upon forward-looking statements within the meaning of the Securities Litigation Reform Act of 1995. Forward-looking statements relate to expectations or forecasts of future events. These statements can be identified by the fact that they do not relate strictly to historical or current facts. They include words such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe,” and other words and terms of similar meaning in connection with a discussion of potential future events, circumstances or future operating or financial performance. In particular, these include statements relating to future actions, prospective products or product approvals, future performance or results of current and anticipated products, sales efforts, expenses, the outcome of contingencies such as legal proceedings, and financial results. Any or all of our forward-looking statements here or in other publications may turn out to be incorrect. They can be affected by inaccurate assumptions or by known or unknown risks and uncertainties. Many such factors will be important in determining our actual future results. Consequently, no forward-looking statement can be guaranteed, and forward-looking statements may be adversely affected by factors, including general market conditions, competitive product development, product availability, current and future branded and generic competition, federal and state regulations and legislation, manufacturing issues, timing of the elimination of trade buying, patent positions, litigations and investigations. Our actual results may vary materially, and there are no guarantees about the performance or valuation of GeneOne stock. It is also important to read the disclosure notice contained in many of the individual GeneOne documents available on the website, as many contain important information on such cautionary factors as of the date of the individual document. We undertake no obligation to correct or update any forward-looking statements, whether as a result of new information, future events or otherwise. You are advised, however, to consult any further disclosures we make on related subjects in our reports.
View the release on PRWeb: http://www.prweb.com/releases/2018/02/prweb15236573.htm
Christy Franco, PhD
Business Development Manager